What Researchers Did
Researchers studied 12 patients with osteonecrosis undergoing hyperbaric oxygen therapy, collecting serial blood samples to assess oxidative stress using plasma F2-isoprostanes.
What They Found
They found that hyperbaric oxygen therapy, administered at a maximum pressure of 2.4 atm with up to 100% oxygen for 119 minutes, did not worsen oxidative stress. This was assessed by measuring plasma F2-isoprostanes in the 12 studied patients.
What This Means for Canadian Patients
For Canadian patients receiving hyperbaric oxygen therapy for conditions like osteonecrosis, these findings suggest that the treatment may not significantly increase oxidative stress. This could offer reassurance regarding a potential concern associated with oxygen exposure during therapy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A primary limitation of this study is its small sample size of only 12 patients.